LFSS 2024: When will the medical devices new measures be applicable?
In its decision no. 2023-860 DC of December 21, 2023, the Constitutional Council ruled on the conformity with the Constitution of…
LFSS 2024: When will the pharmaceutical products new measures be applicable?
In its decision no. 2023-860 DC of December 21, 2023, the Constitutional Council ruled on the conformity with the Constitution of…
LFSS 2024: new paybacks to penalise medical devices with a negative environmental impact
On December 4, 2023, the French National Assembly definitively adopted the Social Security Financing Bill (PLFSS) on final reading without voting. Article…
PLFSS 2024: a new reimbursement regime post early access
Early access makes it possible to finance treatments that are presumed to be innovative and often expensive. However, once this…
Contradictory procedure: what’s at stake in terms of market access?
Many decisions concerning the reimbursement of healthcare products must be preceded by a contradictory procedure. The aim of this procedure…
Mission Borne: toward a redefinition of conventional policy?
The Borne Mission[1] recommends reforming certain aspects of healthcare product pricing. It proposes, for example, that new factors be taken into…